Par Pharmaceutical Companies, Inc.,  a US-based specialty pharmaceutical company, has started shipping all strengths of modafinil tablets, a generic version of Teva's Provigil brand. Par's initial shipments will comprise generically-labeled presentations of the Provigil product.

Par acquired the US marketing rights to modafinil from Teva in connection with Teva's acquisition of Cephalon in 2011. According to IMS Health data, annual sales in the US for Provigil are approximately $1.1 billion.

Modafinil is a wakefulness-prompting agent for oral administration. It is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), and shift work disorder.  In OSA, modafinil is indicated as an adjunct to standard treatment(s) for the underlying obstruction.

Modafinil is contraindicated in patients with a known hypersensitivity to modafinil, armodafinil or its inactive ingredients.